Rheumatology and COVID-19
Revue Medicale Suisse
; 16(691):831-834, 2020.
Article
in French
| EMBASE | ID: covidwho-2322863
ABSTRACT
Current pandemic implies changes in patient care in rheumatology to reduce the risk of coronavirus transmission to patients visiting health-care facilities, by organizing less frequent blood tests, using teleconsultations, and switching from intravenous to subcutaneous drug administration. Patients under immunosuppressive treatment are considered at high risk of severe outcome and are protected accordingly by the Swiss authorities. However, current, scarce scientific evidence suggests that patients under immunosuppressive therapy do not necessarily develop severe COVID-19 presentations. Therefore, the current guidelines recommend pursuing the treatment throughout the pandemic. In case of SARS-CoV-2 infection, immunosuppressive drugs should be temporarily stopped, except for glucocorticoids, hydroxychloroquine and sulfasalazine.Copyright © 2020 Editions Medecine et Hygiene. All rights reserved.
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
French
Journal:
Revue Medicale Suisse
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS